Journal
LEUKEMIA RESEARCH
Volume 37, Issue 10, Pages 1329-1340Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.06.023
Keywords
Acute myeloid leukemia; Homoharringtonine; Aclarubicin; Synergistic; beta-Catenin
Categories
Funding
- National Natural Science Foundation of China [81070418]
- Zhejiang Provincial Science and Technology Foundation of China [2012C33G2010243]
Ask authors/readers for more resources
In this study, we confirmed that combining HHT with ACR can result in synergistic cytotoxicity to AML cells in vitro and in vivo. Combining HHT and ACR simultaneously inhibited PI3K/AKT and WNT/beta-catenin signaling in AML cells. Significant increases in growth inhibition and apoptosis were induced by an AKT inhibitor when the WNT3A gene of THP-1 cells was silenced. HHT + ACR could synergistically induce the apoptosis of CD34(+)/CD38(-) primary AML cells. These results highlight beta-catenin and AKT are promising targets for combination therapy for AML. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available